Refine your search
Collections
Co-Authors
- Leena Sahu
- Amit Roy
- Prasanna Kumar Panda
- Ghanshyam Dhalendra
- Suresh Kumar Ghritlahare
- Geetanjali Mishra
- Jhakeshwar Prasad
- Ashish Kumar Netam
- Mahendra Kumar Sahu
- Hemlata Dewangan
- Kiran P. Narkhede
- Bibhas Pandit
- Pooja Tiwari
- Vandna Dewangan
- Ram Kumar Sahu
- Abinash Satapathy
- Kunal Chandrakar
- Suruj Kaushik
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Satapathy, Trilochan
- A Phytopharmacological Review on Lawsonia inermis L.
Abstract Views :374 |
PDF Views:1
Authors
Affiliations
1 Columbia Institute of Pharmacy, Tekari, Raipur, C.G., IN
2 Columbia Institute of Pharmacy, Tekari, Raipur C.G, IN
1 Columbia Institute of Pharmacy, Tekari, Raipur, C.G., IN
2 Columbia Institute of Pharmacy, Tekari, Raipur C.G, IN
Source
Research Journal of Science and Technology, Vol 4, No 3 (2012), Pagination: 93-107Abstract
Medicinal plants have very important place as they not only maintain the health and vitality of human beings and animals. India is the largest producer of medicinal plants and is rightly called the “Botanical Garden of the World”. The plant Lawsonia inermis L. (family- Lythraceae) commonly known as Henna or Mehndi is known for its cosmetic properties. This plant has relabeled that use of wildlife medicinal resources in the concern not only from conservation point of view but in the therapeutic point of view. Henna plant is a much branched glabrous shrub or small tree, cultivated for its leaves although stem bark, ischolar_mains, flowers and seeds have also been used in traditional medicine. The plant has been reported the various in-vitro and in-vivo studies to have antifungal, antibacterial, antiviral, antimicrobial, immunostimulant, wound healing, analgesic, hepatoprotective, antiinflammatory, antiparasitic, antitrypanosomal, antioxidant, antifertility, tuberculostatic, anticancer, enzyme inhibitory, memory and behaviour effectiveness, antitrypanosomal, antisickling, antidiabetic, and many other properties. Henna, the potential medicinal plant is the unique source of various pharmacologically important compounds. This review gives a bird’s eye view mainly on the pharmacognostic characteristics, traditional uses, phytochemistry and pharmacological actions of the plant.Keywords
Lawsonia inermis L., Traditional Medicine, Antiinflammatory, Enzyme Inhibitory, Phytochemistry, Pharmacological Actions.- Solid Lipid Nanoparticles:A Novel Carrier in Drug Delivery System
Abstract Views :283 |
PDF Views:0
Authors
Affiliations
1 Dept of Pharmacology, Columbia Institute of Pharmacy, Raipur, C.G, Pin-493 111, IN
2 University Department of Pharmaceutical Sciences, Utkal University, VaniVihar, Bhubaneswar, Odisha, IN
1 Dept of Pharmacology, Columbia Institute of Pharmacy, Raipur, C.G, Pin-493 111, IN
2 University Department of Pharmaceutical Sciences, Utkal University, VaniVihar, Bhubaneswar, Odisha, IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 5, No 2 (2013), Pagination: 56-61Abstract
The era of nanotechnology has revolutionized the drug delivery system and persuades new research strategies to flourish. Solid lipid nanoparticles (SLN) has attracted various research groups and companies since the early 1990s, however research in the SLNs is still in its infancy. Recently, increasing attention has been focused on these SLN as colloidal drug carriers for incorporating hydrophilic or lipophilic drugs. These lipid nanoparticles modify drug release, body distribution and kinetics of associated drugs. Other applications of SLNs are tissue/cell targeting of drugs and reduction of unwanted side effects by controlled release. The prospect of improved cancer chemotherapy using solid lipid nanoparticles (SLN) as a drug delivery system is also promising. Several obstacles frequently encountered with anticancer compounds, such as normal tissue toxicity, poor specificity and stability and a high incidence of drug resistant tumor cells, are at least partially overcome by delivering them using SLN. The present review focuses on the utility of SLN in terms of their advantages, production methodology, characterization and applications. If properly investigated; SLNs may open new vistas in therapy of complex diseases.Keywords
Solid Lipid Nanoparticles, Drug Delivery, Colloidal Drug Carriers, Applications of SLNs.- Animal Models for Inflammation:A Review
Abstract Views :247 |
PDF Views:1
Authors
Affiliations
1 Columbia Institute of Pharmacy, Tekari, Near Vidhan Sabha, Raipur-493111, Chhattisgarh, IN
1 Columbia Institute of Pharmacy, Tekari, Near Vidhan Sabha, Raipur-493111, Chhattisgarh, IN
Source
Asian Journal of Pharmaceutical Research, Vol 3, No 4 (2013), Pagination: 207-212Abstract
Inflammation is reaction of living tissues towards injury, and comprises systemic and local responses. Inflammation is part of the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. Inflammation is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue. The nature of the inflammatory response following tissue injury depends upon both the time elapsed since injury as well as the extent of tissue damage. Inflammation can be classified as either acute or chronic. Acute inflammation is usually of short duration and sudden onset. The typical sequence of events is an initial transient arteriolar constriction followed by vasodilation, increased vascular endothelial permeability, exudation of fluid and plasma proteins, and transmigration of leukocytes from vessels into the injured tissues. Chronic inflammation can begin 2-4 days after the onset of the acute response. Chronic inflammation on the contrary is granuloma formation. Inflammation research involves a number of experimental models to study the anti-inflammatory activity. The anti-inflammatory agents exert their effect through a spectrum of different modes of action. The anti-inflammatory activity of new substances can be evaluated by using various pre clinical screening method. Use of various phlogestic agent like carragenan, brewer's yeast, dextran, egg albumin, kaolin, aerosil, croton oil, and cotton wool inflammation is induced and the amount of decrease in its inducing characteristics is measured.Keywords
Inflammation, Paw Edema, Erythema, Edema, Granuloma, Arthritis.- Ethnopharmacological Story of Guggul Sterones:An Overview
Abstract Views :191 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, Columbia Institute of Pharmacy, Tekari, Near Vidhan Sabha, Raipur -493111 Dist-Raipur (C.G.), IN
2 University Department of Pharmaceutical Sciences, Utkal University, Vanivihar, Bhubaneswar, Odisha-751004, IN
3 School of Pharmaceutical Education and Research, Berhampur University, Odisha-760007, IN
1 Department of Pharmacology, Columbia Institute of Pharmacy, Tekari, Near Vidhan Sabha, Raipur -493111 Dist-Raipur (C.G.), IN
2 University Department of Pharmaceutical Sciences, Utkal University, Vanivihar, Bhubaneswar, Odisha-751004, IN
3 School of Pharmaceutical Education and Research, Berhampur University, Odisha-760007, IN
Source
Research Journal of Pharmacognosy and Phytochemistry, Vol 9, No 3 (2017), Pagination: 182-188Abstract
Medicinal plants have played an important role throughout the world in treating and preventing human diseases, commiphora wightii is an important medicinal plant of herbal heritage of India. Guggul is obtained from commiphora mukul which belong to the Family, Burseraceae . C. mukul occurs in north east Africa, Somali and southern Arabia , in India it is found in Gujrat, Mysore , Bengal, M. Pradesh , Desert of Rajastasthan a list of few Commiphora species C. Mukul, C. Myrrh , C. Stocksiana Engl, C. Caudate Engl. etc, Guggul tree is small ,1.2-1.8 m high. Each plant yield about one kilogram of the product which is collected in cold Season, isolation of guggul sterons , extract with EtOAC yield soluble fraction and insoluble fraction, soluble fraction consist of 45% gum resin while 55% insoluble fraction contains carbohydrate, there is no any therapeutic property reported. Guggul lipid has active ingredients like Ketosteroids cis and trans is also known as sterones. guggulsterone-I, II, III, IV, V, VI, myrcene, dimyrcene, bioactive compounds in extract of mukul reported are dimyrcene, 15 α- camphorene. 16 linoleic, oleic, stearic, palmitic acid, sitosterol etc. It is therapeutically used in obesity hyperlipidaemia, arthritis, coronary thrombosis, cardiac disorders, diabetes, tumours, thyroid disorders, hepatic obstructions and weakness pharyngitis etc. Marketed formulation of Guggul triphala Guggul, Yougaraja Guggul, kaishora gugguln, Navaka guggul etc.Keywords
Commiphora Mukul, Chemistry, Guggul Lipid, Therapeutic Uses.References
- Singh A, Chawhan ES, Tiwari A. Phytochemical Screening Of Commniphora Mukul Seeds And Bark Powder-A Comparative Studies. International Journal for Innovative Research in Science and Technology. 2016 : 2(9):157-9.
- Bhardwaj Shivangi, Renuka, Shukla VJ.Optimization of mobile phase by simplex method with special reference to guggulu (commiphora wightii). International Journal of Pharmacy. 2014:4(3): 129-134.
- Xiao M, Xiao D. Gugulipid, an Extract of Ayurveda Medicine Plant Commiphora Mukul as a potent agent for cancer chemoprevention and cancer chemotherapy. Medicinal chemistry. 2012 :2(6):1-2.
- Dubey D, Prashant K, Jain SK. In-vitro antioxidant activity of the ethyl acetate extract of gum guggul (Commiphora mukul). In Biological Forum-An Int. J. 2009: 32-35.
- Krishnamurthy G, Tiwari S K., Pandey Amit and Yadav SS. RAPD Markers for Genetic Diversity Assessment of Critically Endangered Medicinal Plant Commiphora wightii (Arn.) Bhandari. International Journal of Current Research in Biosciences and Plant Biology. 2015:2(8): 29-34.
- Vyas P, Joshi R. Assessment of molecular variations among different biotypes of Commiphora wightii (Arnott.) Bhandari, using RAPD markers. International Journal of Innovative Science, Engineering and Technology. 2015: 2(6):328-38.
- Goyal P, Chauhan A, Kaushik P. Assessment of Commiphora wightii (Arn.) Bhandari (Guggul) as potential source for antibacterial agent. Journal of Medicine and Medical Sciences. 2010:1(3):71-75.
- D.Kumar, Mishra DK and Sharma SK. Sharma Standardization of Agronomic Practices for Commiphora wightii (Arnott) Bhandari. An Important Medicinal Plant of Indian Desert Forestry Bulletin. 2012:12(2): 69-72.
- Ramesh B et al. Effect of Commiphora mukul gum resin on polyol pathway and intestine disaccharidases enzymes of insulin deficient and fructose fed insulin resistant rats. Indo American Journal of Pharma Research.2014: (12):1559-5906.
- Ramesh B, Saralakumari D. Antihyperglycemic, hypolipidemic and antioxidant activities of ethanolic extract of Commiphora mukul gum resin in fructose-fed male Wistar rats. Journal of physiology and biochemistry. 2012: 68(4):573-82.
- Agrawal N, Kumar A. In Recent era: Indication of Guggulu (Commiphora wightti) IN Human disorders. Medical Science Global Journal for Research Analysis.2015: 4(1):128-130.
- Dave R.P, Patel S. Gugulu plant of Jambudia vidi at Saurashtra region: A review of the medicinal evidences for its Remedial properties. Research and Review in bioscience. 2014:9(7): 231-236.
- Masten SA. Toxicological summary for gum guggul and some of its steroidal constituents. NTP/NIEHS, National Institutes of Health, US Department of Health and Human Services, Research Traingle Park, North Carolina. 2005:1-38.
- Azam Roohi, Mushtaq Shafia, Nisar Shubrin. Muqil (commiphora mukul) –a Wonder Drug inTraditional Medicine. International Journal of Institutional Pharmacy and Life Sciences .2015: 5(3):286-295.
- Singh DC, Dhyani S, Kaur G. A critical review on guggulu [Commiphora wightii (Arn.) Bhand.] and its miraculous medicinal uses. International Journal of Ayurveda and Pharma Research. 2015: 3(1).1-9.
- Sharma S, Kumar A. Traditional Uses of Herbal Medicinal Plants of Rajashthan: Guggal. International Journal of Life Science and Pharma Research. 2012:2(4):77-82.
- Poonia P, Mittal SK., Gupta V K, Singh J, Sweety. Gum Guggul: An Ayurvedic Boom. International Journal of Pharmacognosy and Photochemical Research 2014: 6(2): 347-354.
- Sagar PK. Adulteration and substitution in endangered, ASU herbal medicinal plants of India, their legal status, scientific screening of active phytochemical constituents. International Journal of Pharmaceutical Sciences and Research. 2014: 5(9):4023.
- Pragnesh N Dave1, Lakha V Chopda. Review on biological activity and determination of EandZGuggulsterones concentration by HPLC and HPTLC Methods. International Journal of Chemical Studies, 2013:1(3):166-170.
- Chaudhary GU. Pharmacological properties of Commiphora wightii arn. Bhandari–An overview. International Journal of Pharmacy and Pharmaceutical Sciences. 2012:4(3):73-5.
- Hanus LO, Rezanka T, Dembitsky VM, Moussaieff A. Myrrh-commiphora chemistry. Biomedical papers. 2005:149(1):3-28.
- Taru P, Abhyankar M, Undale V, Bhosale A. Acute and subacute toxicity studies on Shodhana processed guggul. International Journal of Pharmaceutical Sciences and Research. 2013 : 4(2):796.
- Jaiswal S, Bara J.K, Soni R,Saksena P, Medical uses of Commiphora Wightii. IOSR Journal of Nursing and Health Science 2016:5(5):76-81.
- Siddiqui MZ, Mazumder PM. Comparative study of hypolipidemic profile of resinoids of Commiphora mukul/Commiphora wightii from different geographical locations. Indian journal of pharmaceutical sciences. 2012:74(5):422.
- Ajay J Parikh, Krishna KL. Antiamnesic Activity of Guggul Extract on Scopolamine Induced Amnesia in Mice. International Journal of Pharmacy 2013; 3(2): 403-409.
- Ding X, Staudinger JL. The ratio of constitutive androstane receptor to pregnane X receptor determines the activity of guggulsterone against the Cyp2b10 promoter. Journal of Pharmacology and Experimental Therapeutics. 2005: 314(1):120-7.
- Brobst DE, Ding X, Creech KL, Goodwin B, Kelley B, Staudinger JL. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. Journal of Pharmacology and Experimental Therapeutics. 2004: 310(2):528-35.
- Claudel T, Staels B, Kuipers F. The Farnesoid X receptor a molecular link between bile acid and lipid and glucose metabolism. Arteriosclerosis, thrombosis, and vascular biology. 2005:25(10):2020-30.
- Sarup P, Bala S, Kamboj S. Pharmacology and phytochemistry of oleogum resin of Commiphora wightii (Guggulu). Scientifica. 2015.1-14.
- Jain Anurekha, Gupta VB. Chemistry and Pharmacological Profile of Guggul a Review. Indian journal of Traditional Knowledge. 2006:5(4): 478-483.
- Barve K, Bhonsle N. Commiphora mukul Prevents Myocardial Dysfunction in Streptozotocin Induced Diabetic Rats. Pharmaceutical crops.2014:5:61-66.
- Sudhakara G, Ramesh B, Mallaiah P, Sreenivasulu N, Saralakumari D. Protective effect of ethanolic extract of Commiphora mukul gum resin against oxidative stress in the brain of streptozotocin-induced diabetic Wistar male rats. EXCLI J. 2012:11:576-92.
- Shishodia S, Aggarwal BB. Guggulsterone inhibits NF-κB and IκBα kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. Journal of Biological Chemistry. 2004: 279(45):47148-58.
- Current Concepts in Clinical Based Management of Diabetic Foot Infections:A Review
Abstract Views :238 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, Columbia Institute of Pharmacy, Tekari, Near Vidhansabha, Raipur -493111Dist- Raipur (C.G.), IN
1 Department of Pharmacology, Columbia Institute of Pharmacy, Tekari, Near Vidhansabha, Raipur -493111Dist- Raipur (C.G.), IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 9, No 3 (2017), Pagination: 157-166Abstract
Diabetic foot ulcers (DFUs) are potentially mortifying complications in need of multidisciplinary endeavour. Imbalance of harmony in glucose homeostasis causes hyperglycemic status which in turn leads to activation of certain metabolic pathways subsequently that lead to development of vascular insufficiency, nerve damages headed by ulceration in lower extremity due to plantar pressures and foot deformity. The standard of care for DFUs consists of several conventional treatments such as, daily wound care dressings, off loading, infection control, glucose control and adequate Perfusion etc. Still the reported healing rate varied between 20.0% and 46.2%.So some newly invented therapies such as negative pressure therapy, topical therapies, hyperbaric oxygen therapy, growth factors, and other antibiotic therapies took upper hand over the conventionally used medications for the treatment of diabetic foot infections. These new therapies also bring about new opportunities for DFU patients. In this review our efforts have been devoted to summarize the various treatments available along with possible mechanism of action for the effective treatment of diabetic foot ulcers.Keywords
Diabetic Foot Infections, Diagnosis, Becaplermin, PDGF, Antibiotic Therapy.References
- 1.Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2•7 million participants. Lancet 378: 3140.
- International Diabetes Federation (2012) The Global Burden. IDF Diabetes Atlas Fifth Edition.
- Malik VS, Popkin BM, Bray GA, Després JP, Hu FB (2010) Sugar sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 121: 1356-1364.
- DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-986.
- National Institute for Health and Clinical Excellence. Diabetic foot problems: inpatient management of diabetic foot problems. Clinical guideline 119. London: NICE, 2011. Accessed March 2013, Abetz L, Sutton M, Brady L, et al. The diabetic foot ulcer scale: a quality of life instrument for use in clinical trials. Pract Diab Int 2002; 19: 167-75.
- Schaper NC, Van Netten JJ, Apelqvist J, et al. Prevention and Management of Foot Problems in Diabetes: A Summary Guidance for Daily Practice Based on the 2015 IWGDF Guidance Documents. Diab Metab Res Rev. DOI:10.1002/dmrr.2695.
- Jane Kelly, M.D. Director, National Diabetes Education Program CDC National Center for Chronic Disease Prevention and Health Promotion page no 1
- Harikumar K, Kumar Bk, Hemalatha Gj, Kumar Mb, Lado Sf. A Review On Diabetes Mellitus. International Journal Of Novel Trends In Pharmaceutical Sciences
- Rabbani N, Alam SS, Riaz S, Larkin JR, Akhtar MW, Shafi T, Thornalley PJ. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia. 2009 Feb 1;52(2):208-12.
- Pendey SP (2010) Understanding diabetic foot. Int J Diabetes Dev Ctries 30:75-79.
- Jeffcoate WJ, Harding KG (2003) Diabetic foot ulcers. Lancet 361: 1545-1551.
- Aguilar F, ”Diabetic Neuropathy” for doctors, Plast and Rest Neural, 4, 1-2, (2005), pp 35-47. ISSN 1665-3254 2005, Boulton AJM, 2003.
- Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990; 13: 513– 521.
- Uc¸ kay I, Hoffmeyer P, Lew D, Pittet D. Prevention of surgical site infections in orthopaedic surgery and bone trauma: state-oftheart update. J Hosp Infect 2012; 84: 5–12.
- Pataky Z, Assal JP, Conne P, Vuagnat H, Golay A. Plantar pressure distribution in type 2 diabetic patients without peripheral neuropathy and peripheral vascular disease. Diabet Med 2005; 22: 762–767.
- Pataky Z, Vischer U. Diabetic foot disease in the elderly. Diabetes Metab 2007; 33: 56–65.
- 17.Peeters P, Verbist J, Keirse K, Callaert J, Deloose K, Bosiers M. Endovascular procedures and new insights in diabetic limb salvage. J Cardiovasc Surg (Torino) 2012; 53: 31–37.
- Pataky Z, Golay A, Bounameaux H, Bobbioni-Harsch E, Assal JP. Relationship between peripheral vascular disease and high plantar pressures in diabetic neuro-ischaemic patients. Diabetes Metab 2003; 29: 489–495.
- Apelqvist J, Castenfors J, Larsson J. Wound classification is more important than site of ulceration in the outcome of diabetic foot ulcers. Diabet Med 1989; 6:526-530.
- Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am. J. Surg. 1998; 176(Suppl. 2A):5S–10S.
- Apelqvist J, Castenfors J, Larsson J. Wound classification is more important than site of ulceration in the outcome of diabetic foot ulcers. Diabet Med 1989; 6:526-530.
- Oyibo SO, Jude EB, Tarawneh I, et al. The effect of ulcer size and site, patient’s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabet Med 2001; 18(2):133-138.
- Margolis DJ, Kantor J, Santanna J, et al. Risk factors for delayed healing of neuropathic diabetic foot ulcers: A pooled analysis. Arch Dermatol 2000; 136(12):1531-1535.
- Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: The association of wound size, wound duration, and wound grade on wound healing. Diabetes Care 2002; 25(10): 835-1839.
- Pecoraro RE, Ahroni J, Boyko EJ, et al. Chronology and determinants of tissue repair in diabetic lower extremity ulcers. Diabetes 1991; 40: 1305-1313.
- McNeely MJ, Bokyo EJ. Diabetes related comorbitidies in Asian Americans: Results of a National Health Survey. J Diabetes Complications 2005; 19(2):101-106.
- Oyibo SO, Jude EB, Tarawneh I, et al. The effect of ulcer size and site, patient’s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabet Med 2001; 18(2):133-138.
- Margolis DJ, Kantor J, Santanna J, et al. Risk factors for delayed healing of neuropathic diabetic foot ulcers: A pooled analysis. Arch Dermatol 2000; 136(12):1531-1535.
- Margolis DJ, Kantor J, Santanna J, et al. Risk factors for delayed healing of neuropathic diabetic foot ulcers: A pooled analysis. Arch Dermatol 2000; 136(12):1531-1535.
- Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: The association of wound size, wound duration, and wound grade on wound healing. Diabetes Care 2002; 25(10): 835-1839.
- Pecoraro RE, Ahroni J, Boyko EJ, et al. Chronology and determinants of tissue repair in diabetic lower extremity ulcers. Diabetes 1991; 40: 1305-1313.
- Sheehan P, Jones P, Caselli A, et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 2003; 26(6):1879-1882.
- McNeely MJ, Bokyo EJ. Diabetes related comorbitidies in Asian Americans: Results of a National Health Survey. J Diabetes Complications 2005; 19(2):101-106.
- Abbott CA, Vileikyte L, Williamson S, et al. Multicentre study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabete Care 2004; 94(5):379–83.
- Kumar S, Ashe HA, Parnell LN, et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet. Med. 1994; 11: 480–484.
- Walters DP, Gatling W, Mullee MA, et al. The distribution and severity of diabetic foot disease: A community study with comparison to a non-diabetic group. Diabet Med 1992; 9:354-358.
- Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW (1995) Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA 273: 721-723.
- Boulton AJ, Kirsner RS, Vileikyte L (2004) Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 351: 48-55.
- Mayfield JA, Sugarman JR (2000) The use of the Semmes-Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes. J Fam Pract 49: S17-29.
- Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW (1994) Assessment and management of foot disease in patients with diabetes. N Engl J Med 331: 854-860.
- Rogers LC, Bevilacqua NJ (2008) The diagnosis of Charcot foot. Clin Podiatr Med Surg 25: 43-51,
- Unger J, Cole BE (2007), Recognition and management of diabetic neuropathy. Prim Care 34: 887-913.
- Illigens BM, Gibbons CH (2009) Sweat testing to evaluate autonomic function.Clin Auton Res 19: 79-87.
- Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, et al. (1976) Correlation of Glucose Regulation and Hemoglobin AIc in Diabetes Mellitus. N Engl J Med 295: 417-420.
- Rabjohn L, Roberts K, Troiano M, Schoenhaus H (2007) Diagnostic and prognostic value of erythrocyte sedimentation rate in contiguous osteomyelitis of the foot and ankle. J Foot Ankle Surg 46: 230-237.
- Boulton AJ, Kirsner RS, Vileikyte L (2004) Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 351: 48-55.
- Tiktin M, Celik S and Berard L. Understanding adherence to medications in type 2 diabetes care and clinical trials to overcome barriers: a narrative review. CurrMed Res Opin 2016; 32: 277– 287.
- Tesfaye S, Boulton AJM and Dickenson A. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 2013; 36: 2456–2465.
- Hsu CR, Chang CC, Chen YT, Lin WN and Chen MY. Organization of wound healing services: the impact on lowering the diabetes foot amputation rate in a ten-year review and the importance of early debridement. Division of Plastic Surgery, Chang Gung memorial hospital, Taiwan. Diabetes Res ClinPract 2015; 109: 77–84.
- Armstrong DG, Lavery LA, Wu S and Boulton AJ. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. Diabetes Care 2005; 28: 551–554.
- Hilton JR, Williams DT, Beuker B, Miller DR and Harding KG. Wound dressings in diabetic foot disease. Clin Infect Dis 2004; 39: S100–S103.
- Dumville JC, Deschpande S, O’Meara S and Speak K. Hydrocolloid dressings for healing diabetic foot ulcers. Cochrane Database Syst Rev Issue 2012; 2: CD009099.
- Jude EB, Apelqvist J, Spraul M and Martini J. Silver dressing study group. Prospective randomized controlled study of hydrofiber dressing containing ionic silver or calcium alginate dressing in nonischaemic diabetic foot ulcers. Diabet Med 2007; 24: 280–288.
- Health Quality Ontario. Negative Pressure Wound Therapy: an evidence-based analysis. Ont Health Technol Assess 2006; 6: 1– 38.
- Greenhalgh DG. The role of growth factors in wound healing. J Traum Inj Infc Clin Care 1966; 41: 159–87.
- Singer AL, Clark RAF. Cutaneous wound healing. N Engl J Med 1999; 341: 738–46.
- Bennett NT, Schultz GS. Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am J Surg 1993; 166: 74–81.
- Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Rep Reg 1996; 4: 411–20.
- Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 2004; 9: 283–89.
- Bowler PG. Wound pathophysiology, infection and therapeutic options. Ann Med 2002; 34: 419–27.
- Goldman R. Growth factors and chronic wound healing: past, present and future. Adv Skin Wound Care 2004; 17: 24–35.
- Robson MC. Cytokine manipulation of the wound. Clin Plast Surg 2003; 30: 57–65.
- Stadelmann WK, Digenis AG, Tobin GR. Physiology and healing dynamics of chronic cutaneous wounds. Am J Surg 1998; 176(2A suppl):26S-38S.
- Hart CE, Bailey M, Curtis DA, et al. Purification of PDGF-AB and PDGF-BB from human platelet extracts and identification of all PDGF dimmers in human platelets. Biochemistry 1990;29: 166–77.
- Nagai MK, Embil JM. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin Biol Ther 2002; 2: 211–8.
- Meyer-Ingold W. Wound therapy: growth factors as agents to promote healing. Trends Biotechnol 1993; 11: 387–92.
- Hart CE, Forstrom JW, Kelly JD, et al. Two classes of PDGF receptor recognize different isoforms of PDGF. Science 1988; 240: 1529–31.
- Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem 1991; 45: 319–26.
- 69. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A (2003) Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes care 26: 1879-1882.
- http://www.iodine.com/drug/regranex/fda-package-insert.
- Nedeljković-Beleslin B, Beleslin D. Becaplermin: A new effective and safe adjuvant topical therapy in patients with chronic neuropathic diabetic foot ulcer. Medicus. 2005;6(3):25-9.
- Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA (2000) Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. Arch Dermatol 136: 1531-1535.
- Boyko EJ, Lipsky BA. Infection and diabetes mellitus. In Harris MI (ed): Diabetes in America, 2nd edition. NIH publication No 95-1468. Bethesda, MD: National Institute of Health. 1995, pp 485-499.
- Muller LM, Gorter KJ, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41(3): 281-288.
- Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot?. Diabetes Metab. Res. Rev 2000;16:S75–S83.
- Anandi C, Alaguraja D, Natarajan V, Ramanathan M, Subramaniam CS, Thulasiram M, Sumithra S. Bacteriology of diabetic foot lesions. Indian Journal of Medical Microbiology 2004; 22(3): 175-178.
- Tice A, Hoaglund P, Giani G, et al. Outcomrs of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003; 114(9): 723-728.
- Lipsky BA, McDonald D, Litka PA. Treatment of infected diabetic foot ulcers: Topical MSI-78 vs. oral ofloxacin (abstract) Diabetologia 1997; 40(1): 482.
- Raymakers JT, Houben AJ, et al. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabetic Medicine 2001; 18(3): 229-234.
- Armstrong DG, Stephan KT, Joseph, et al. What is the shelf life of physician- mixed antibiotic-impregnated calcium sulphate pellets? J Foot Ankle Surg 2003, 42(5): 302-304.
- Van Damme H, Rorive M, Lavery LA, et al. Amputations in diabetic patients: A plea for footsparing surgery. Acta chir Belg 2001; 101(3): 123-129.
- Rauwerda JA. Surgical treatment of the infected diabetic foot. Diabetes Metab Rs Rev2004, 20(1): S41-S44.
- Tan JS, Friedman NM, Hazelton-Miller C, et al. Can aggressive treatment of diabetic foot infection reduce the need for above-ankle amputation? Clin Infect Dis 1996; 23: 286-291.
- Pancreatic Polypeptide:Biologically Active Neuropeptide and their Clinical Significance
Abstract Views :457 |
PDF Views:0
Authors
Affiliations
1 Columbia Institute of Pharmacy, Tekari, Raipur, Chhattisgarh, Pin-493111, IN
1 Columbia Institute of Pharmacy, Tekari, Raipur, Chhattisgarh, Pin-493111, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 9, No 4 (2017), Pagination: 211-218Abstract
Imbalances in normal regulation of food intake can cause obesity and related disorders. Pancreatic polypeptide (PP) share considerable amino acid sequence homology act as a robust anorexigenic hormone effectively modulates food intake and energy homeostasis, thus potentially aiding anti-obesity therapeutics. They are found in widely disparate locations, including the pancreas (PP), the distal gut (PYY), and the central nervous system (NPY). Intra-gastric and intra-intestinal infusion of nutrients stimulate PP secretion from the gastrointestinal tract, in turn that causes vagal stimulation and exerts complex actions via the neuropeptide Y4 receptor (Family of G-protein coupled Receptors) in arcuate nucleus of the hypothalamus, there by subsequently activating key hypothalamic nuclei and dorsal vagal complex of the brainstem to influence energy homeostasis and body composition. In this review our efforts have been devoted to summarize the detail about the pancreatic polypeptide their functions and mechanisms.Keywords
Pancreatic Polypeptide, Anorexigenic Hormone, Vagal Stimulation, Obesity.References
- Hart PA, Baichoo E, Bi Y, Hinton A, Kudva YC, Chari ST. Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus. Pancreatology. 2015 Apr 30;15(2):162-6.
- Gingerich RL, Lacy PE, Chance RE, Johnson MG. Regional pancreatic concentration and in-vitro secretion of canine pancreatic polypeptide, insulin, and glucagon. Diabetes. 1978 Feb 1;27(2):96-101.
- Rahier J, Wallon J, Gepts W, Haot J. Localization of pancreatic polypeptide cells in a limited lobe of the human neonate pancreas: remnant of the ventral primordium? Cell Tissue Res. 1979;200(3):359e66.
- Lundberg JM, Tatemoto K. Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to α‐adrenoceptor blockade. Actaphysiologicascandinavica. 1982 Dec 1;116(4):393-402.(8) 5. Haque, Emily; Chand, Rattan. "Milk protein derived bioactive peptides". Dairy Science. Retrieved 28 July 2014.
- Duquesne S, Destoumieux-Garzón D, Peduzzi J, Rebuffat S; Destoumieux-Garzón; Peduzzi; Rebuffat (August 2007). "Microcins, gene-encoded antibacterial peptides from enterobacteria". Natural Product Reports. 24 (4):70834. doi:10.1039/b516237h.PMID 17653356.
- Pons M, Feliz M, AntòniaMolins M, Giralt E; Felsiz; AntòniaMolins; Giralt (May 1991). "Conformational analysis of bacitracin A, a naturally occurring lariat". Biopolymers. 31 (6): 605–12. doi:10.1002/bip.360310604. PMID 1932561.
- Torres AM, Menz I, Alewood PF, et al. (July 2002). "D-Amino acid residue in the C-type natriuretic peptide from the venom of the mammal, Ornithorhynchusanatinus, the Australian platypus". FEBS Letters. 524 (1–3): 172–6. doi:10.1016/S0014-5793(02)03050-8. PMID 12135762.
- Meister A, Anderson ME; Anderson (1983). "Glutathione". Annual Review of Biochemistry. 52 (1)71160. doi:10.1146/annurev.bi.52.070183.003431.PMID 6137189.
- Hahn M, Stachelhaus T; Stachelhaus (November 2004). "Selective interaction between nonribosomal peptide synthetases is facilitated by short communication-mediating domains". Proceedings of the National Academy of Sciences of the United States of America.101(44):1558590. Bibcode:2004PNAS..10115585H.doi:10.1073/pnas.0404932101. PMC 524835 . PMID 15498872.
- Finking R, Marahiel MA; Marahiel (2004). "Biosynthesis of nonribosomal peptides1".AnnualReviewofMicrobiology.58(1):45388.doi:10.11 46/annurev.micro.58.030603.123615. PMID 15487945.
- Du L, Shen B; Shen (March 2001). "Biosynthesis of hybrid peptide-polyketide natural products". Current Opinion in Drug Discovery and Development. 4 (2): 215–28.PMID 11378961.
- http://www.usvpeptides.com
- Payne JW (1976). "Peptides and micro-organisms". Advances in Microbial Physiology. Advances in Microbial Physiology. 13: 55–113. doi:10.1016/S0065-2911(08)60038-7.ISBN 9780120277131. PMID 775944.
- Hummel J, Niemann M, Wienkoop S; et al. (2007). "ProMEX: a mass spectral reference database for proteins and protein phosphorylation sites". BMC Bioinformatics. 8 (1): 216.doi:10.1186/1471-2105-8-216. PMC 1920535 . PMID 17587460.
- Webster J, Oxley D; Oxley (2005). "Peptide mass fingerprinting: protein identification using MALDI-TOF mass spectrometry". Methods in Molecular Biology. Methods in Molecular Biology™. 310: 227–40. doi:10.1007/978-1-59259-948-6_16. ISBN 978-1-58829-399-2. PMID 16350956.
- Marquet P, Lachâtre G; Lachâtre (October 1999). "Liquid chromatography-mass spectrometry: potential in forensic and clinical toxicology". Journal of Chromatography B.733 (1–2): 93–118. doi:10.1016/S0378-4347(99)00147-4. PMID 10572976.
- Lonovics J, Devitt P, Watson LC, Rayford PL, Thompson JC (Oct 1981). "Pancreaticpolypeptide".ArchSurg.116(10):125664.doi:10.1001/a rchsurg.1981.01380220010002. PMID 7025798.
- Batterham, RL; Le Roux, CW; Cohen, MA; Park, AJ; Ellis, SM; Patterson, M; Frost, GS; Ghatei, MA; Bloom, SR (Aug 2003). "Pancreatic polypeptide reduces appetite and food intake in humans". The Journal of Clinical Endocrinology and Metabolism. 88 (8): 3989–92.doi:10.1210/jc.2003-030630. PMID 12915697.
- Boel, E.; Schwartz, T. W.; Norris, K. E.; Fiil, N. P. (April 1984). "A cDNA encoding a small common precursor for human pancreatic polypeptide and pancreatic icosapeptide". EMBO Journal. 3 (4): 909–912. PMC 557446 . PMID 6373251.
- Holzer P, Reichmann F and Farzi A (2012) Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides 46:261-274
- Leiter AB, Keutmann HT and Goodman RH (1984) Structure of a precursor to human pancreatic polypeptide. The Journal of Biological Chemistry 259(23): 14702-14705
- Koska J, DelParigi A, de Courten B, Weyer C and Tataranni PA (2004) Pancreatic polypeptide is involved in the regulation of body weight in Pima indian male subjects. Diabetes 53(12): 3091-3096
- Dembiński A, Warzecha Z, Ceranowicz P, Pawlik M, Dembiński M, Kabat K, Konturek SJ, Kownacki P, Hladki W and Pawlik WW (2004) Influence of central and peripheral administration of pancreatic polypeptide on gastric mucosa growth. Journal of Physiology and Pharmacology 55(1): 223-237
- Kumari A, Sreetama S and Mohanakumar KP (2007) Atropine, a muscarinic cholinergic receptor antagonist increases serotonin, but not dopamine levels in discrete brain regions of mice. Neuroscience Letters 423(2): 100-103
- Tong J, Utzschneider KM, Carr DB, Zraika S, Udayasankar J, Gerchman F, Knopp RH and Kahn SE (2007) Plasma pancreatic polypeptide levels are associated with differences in body fat distribution in human subjects. Diabetologia 50(2): 439-442
- Troke RC, Tan TM and Bloom SR (2014) The future role of gut hormones in the treatment of obesity. Therapeutic Advances in Chronic Disease 5(1): 4-14
- Wynne K, Stanley S, McGowan B and Bloom S (2005) Appetite control. Journal of Endocrinology 184: 291-318
- Sliwińska-Mossoń M, Borowiecka K and Milnerowicz H (2012) Neuropeptides Y, YY, PP and their clinical significance. Neuropeptides 46(6):261-274
- Cabrele C and Beck-Sickinger AG (2000) Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. Journal of Peptide Science 6(3): 97-122
- 1336 Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, Fujino MA, Niijima A, Meguid MM andKasuga M (2003) Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124(5): 1325
- Bozkurt T, Maroske D, Adler G. Exocrine pancreatic function after recovery from necrotizing pancreatitis. Hepato-gastroenterology. 1995 Feb;42(1):55-8.
- https://www.boundless.com/physiology/textbooks/boundless-anatomy-and-physiology-textbook/endocrine-system-16/the-pancreas-159/types-of-cells-in-the-pancreas-798-365/
- Doyle ME, Egan JM (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. PharmacolTher 113: 546-593.
- Holz GG, Leech CA, Heller RS, Castonguay M, Habener JF (1999) cAMP dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). J BiolChem 274:14147-14156.
- Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. ProcNatlAcadSci U S A 84: 3434-3438.
- Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553.
- World Health Organisation. (1999) Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. WHO/NCD/NCS/99.2.
- Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res ClinPract 94: 311-321.
- http://www.diabetes.org.uk/Guide-to-diabetes/Introduction-to-diabetes
- Schwarz PE, Reimann M, Li J, Bergmann A, Licinio J, et al. (2007) The Metabolic Syndrome - a global challenge for prevention. HormMetab Res 39:777-780.
- Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414: 782-787.
- Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52.
- Perley MJ, Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest 46: 1954-1962.
- Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54: 10-18.
- Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S (2008) Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 14: 161-168.
- Meier JJ, Nauck MA (2010) Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 59: 1117-1125.
- Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830.
- Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, et al. (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J ClinEndocrinolMetab 86: 3717-3723.
- Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, et al. (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307.
- Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, et al. (2007) Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 56: 1951-1959.
- Schirra J, Katschinski M, Weidmann C, Schäfer T, Wank U, et al. (1996) Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97: 92-103.
- Vilsbøll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45: 1111-1119.
- Holst JJ, Gromada J (2004) Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J PhysiolEndocrinolMetab 287: E199-206.
- Kjems LL, Holst JJ, Vølund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52: 380-386.
- Nyholm B, Walker M, Gravholt CH, Shearing PA, Sturis J, et al. (1999) Twentyfour- hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia 42: 1314-1323.
- Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, et al. (2004) Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. RegulPept 122: 209-217.
- Holst JJ, Vilsbøll T, Deacon CF (2009) Theincretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297: 127-136.
- Salehi M, Aulinger B, Prigeon RL, D’Alessio DA (2010) Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes 59: 1330-1337.
- Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, et al. (2009) Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 32: 1237-1243.
- Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, et al. (2010) Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized doubleblind placebo-controlled study. Diabet Med 27: 556-562.
- Gallwitz B (2010) The evolving place of incretin-based therapies in type 2 diabetes. PediatrNephrol 25: 1207-1217.
- Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439.
- Coopman K, Huang Y, Johnston N, Bradley SJ, Wilkinson GF, et al. (2010) Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP1)-(7-36) amide and the small-molecule ago-allosteric agent “compound 2” at the GLP-1 receptor. J PharmacolExpTher 334: 795-808.209. Beinborn M, Worrall CI, McBride EW, Kopin AS (2005) A human glucagon like peptide-1 receptor polymorphism results in reduced agonist responsiveness. RegulPept 130: 1-6.
- Thorens B (1992) Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. ProcNatlAcadSci U S A 89: 8641-8645.231. De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, et al. (1995) Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest 96: 2489-2495.
- Holz GG (2004) Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 53: 5-13.
- Matschinsky FM (2002) Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 51 Suppl 3: S394-404.
- Holz GG 4th, Kühtreiber WM, Habener JF (1993) Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361: 362-365.
- Montrose-Rafizadeh C, Egan JM, Roth J (1994) Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action. Endocrinology 135: 589-594.
- Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, et al. (2001) Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276: 46046-46053.
- Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, et al. (2000) cAMPGEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2: 805- 811.
- Kang G, Joseph JW, Chepurny OG, Monaco M, Wheeler MB, et al. (2003) Epac-selective cAMP analog 8-pCPT-2’-O-Me-cAMP as a stimulus for Ca2+- induced Ca2+ release and exocytosis in pancreatic beta-cells. J BiolChem 278: 8279-8285.
- Tsuboi T, da Silva Xavier G, Holz GG, Jouaville LS, Thomas AP, et al. (2003) Glucagon like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochem J 369:287-299.
- Kasai K, Ohara-Imaizumi M, Takahashi N, Mizutani S, Zhao S, et al. (2005) Rab27a mediates the tight docking of insulin granules onto the plasma membrane during glucose stimulation. J Clin Invest 115: 388-396.
- Jhala US, Canettieri G, Screaton RA, Kulkarni RN, Krajewski S, et al. (2003) cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 17: 1575-1580.
- Wang Q, Li L, Xu E, Wong V, Rhodes C, et al. (2004) Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47: 478-487.
- Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, et al. (2005) Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 19: 2199-2211.
- Tokuyama Y, Matsui K, Egashira T, Nozaki O, Ishizuka T, et al. (2004) Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabetes Res ClinPract 66: 63-69.
- Salapatek AM, MacDonald PE, Gaisano HY, Wheeler MB (1999) Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptorm can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.MolEndocrinol 13: 1305-1317.
- Berson, David M. (10 March 2007). "Phototransduction in ganglion-cell photoreceptors". PflügersArchiv - European Journal of Physiology. 454 (5): 849–855.
- Langley J. On the stimulation and paralysis of nerve cells and of nerve-endings. Part 1. J Physiol 1901 October 16; 27(3): 224– 236.
- Signal Transduction Mechanism:A Critical Review
Abstract Views :490 |
PDF Views:0
Authors
Affiliations
1 Columbia Institute of Pharmacy, Tekari, Raipur, Chhattisgarh, Pin-493111, IN
1 Columbia Institute of Pharmacy, Tekari, Raipur, Chhattisgarh, Pin-493111, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 9, No 4 (2017), Pagination: 223-229Abstract
Cellular signaling plays an important role in alteration of cellular physiology and initiation of pharmacological response. Cells usually communicate with each other through extracellular messenger molecules called ligand which can travel a short distance and stimulate cells with the release of second messenger molecule by a cell that is engaged in sending messages to the downward in same cell or to the other cells in the body. Cells can only respond to a particular extracellular message if they express receptors for that ligand specifically recognize and bind that messenger molecule and the interaction between the ligand and receptor induces a conformational change in the receptor that causes the signal to be relayed across the membrane to the receptor’s cytoplasmic domain. A signaling pathway is activated by a diffusible second messenger and another in which a signaling pathway is activated by recruitment of proteins to the plasma membrane. Most signal transduction pathways involve a combination of these mechanisms. In this review we have tried to elaborate diagrammatically the details about the various pathways responsible for signaling for easy understanding for the future research.Keywords
Ligand, Receptors, Signaling, Second Messenger, Pharmacological Response.References
- J. N. Langley. On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curare. J Physiol 1905; 33: 374–413[25] Limbird LE (2004). "The receptor concept: a continuing evolution". Mol. Interv. 4 (6): 326–36
- Limbird LE (2004). "The receptor concept: a continuing evolution". Mol. Interv. 4 (6): 32636
- Hall, JE (2016). Guyton and Hall Textbook of Medical Physiology. Philadelphia, PA: Elsevier Saunders. p. 930-937
- Hall, JE (2016). Guyton and Hall Textbook of Medical Physiology. Philadelphia, PA: Elsevier Saunders. p. 930-937
- Congreve M, Marshall F (March 2010). "The impact of GPCR structures on pharmacology and structure-based drug design". Br. J. Pharmacol. 159 (5): 986–96.
- Congreve M, Marshall F (March 2010). "The impact of GPCR structures on pharmacology and structure-based drug design". Br. J. Pharmacol. 159 (5): 986–96.
- Kou Qin, Chunmin Dong, Guangyu Wu and Nevin A Lambert (August 2011). "Inactive-state preassembly of Gq-coupled receptors and Gqheterotrimers". Nature Chemical Biology. 7 (11): 740–747.
- Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (2012). Rang and Dale's Pharmacology (7th ed.). Elsevier Churchill Livingstone
- Purves, Dale, George J. Augustine, David Fitzpatrick, William C. Hall, Anthony-Samuel LaMantia, James O. McNamara, and Leonard E. White (2008). Neuroscience. 4th ed. Sinauer Associates. pp. 156–7.
- Cascio M (2004). "Structure and function of the glycine receptor and related nicotinicoid receptors". J. Biol. Chem. 279 (19): 19383–6.
- Royal Swedish Academy of Sciences (10 October 2012). "The Nobel Prize in Chemistry 2012 Robert J. Lefkowitz, Brian K. Kobilka". Retrieved 10 October 2012.
- The Top Prescription Drugs of 2012 Globally: Biologics Dominate, But Small Molecule CNS Drugs Hold on to Top Spots" (PDF). ACS Chemical Neuroscience. Retrieved 2016-02-03.
- Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, Filipek S (2012). "Action of molecular switches in GPCRs-theoretical and experimental studies". Current Medicinal Chemistry. 19 (8): 1090–109.
- King N, Hittinger CT, Carroll SB (Jul 2003). "Evolution of key cell signaling and adhesion protein families predates animal origins". Science. 301 (5631): 361–3.
- Filmore D (2004). "It's a GPCR world". Modern Drug Discovery. American Chemical Society. 2004 (November): 24–28, [ Overington JP, Al-Lazikani B, Hopkins AL (Dec 2006). "How many drug targets are there?". Nature Reviews. Drug Discovery. 5 (12): 993–6
- Gilman AG (1987). "G proteins: transducers of receptor-generated signals". Annual Review of Biochemistry. 56 (1): 615–49.
- Wettschureck N, Offermanns S (Oct 2005). "Mammalian G proteins and their cell type specific functions". Physiological Reviews. 85 (4): 1159–204.
- Qin K, Dong C, Wu G, Lambert NA (Oct 2011). "Inactive-state preassembly of G(q)-coupled receptors and G(q) heterotrimers". Nature Chemical Biology. 7 (10): 740–7.
- Wettschureck N, Offermanns S (Oct 2005). "Mammalian G proteins and their cell type specific functions". Physiological Reviews. 85 (4): 1159–204.
- Chen-Izu Y, Xiao RP, Izu LT, Cheng H, Kuschel M, Spurgeon H, Lakatta EG (Nov 2000). "G(i)-dependent localization of beta(2)-adrenergic receptor signaling to L-type Ca(2+) channels". Biophysical Journal. 79 (5): 2547–56.]
- Li E, Hristova K (May 2006). "Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies". Biochemistry. 45 (20): 6241–51.
- Schlessinger J (Nov 1988). "Signal transduction by allosteric receptor oligomerization". Trends in Biochemical Sciences. 13 (11): 443–7.
- Li E, Hristova K (May 2006). "Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies". Biochemistry. 45 (20): 6241–51.
- Roskoski R (Jun 2004). "The ErbB/HER receptor protein-tyrosine kinases and cancer". Biochemical and Biophysical Research Communications. 319 (1): 1–11.
- Wolanin PM, Thomason PA, Stock JB (Sep 2002). "Histidine protein kinases: key signal transducers outside the animal kingdom". Genome Biology. 3 (10): REVIEWS3013.
- Wilson CH, Ali ES, Scrimgeour N, Martin AM, Hua J, Tallis GA, Rychkov GY, Barritt GJ (2015). "Steatosis inhibits liver cell storeoperated Ca(2)(+) entry and reduces ER Ca(2)(+) through a protein kinase C-dependent mechanism". Biochem J. 466: 379– 390.
- Biaggioni I., Robertson D. (2011). Chapter 9. Adrenoceptor Agonists and Sympathomimetic Drugs. In: B.G. Katzung, S.B. Masters, A.J. Trevor (Eds), Basic and Clinical Pharmacology, 11e. Retrieved October 11, 2011
- Barrett KE, Barman SM, Boitano S, Brooks H. Chapter 2. Overview of Cellular Physiology in Medical Physiology. In: K.E. Barrett, S.M. Barman, S. Boitano, H. Brooks (Eds), Ganong's Review of Medical Physiology, 23
- Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548–5557
- Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355–365
- Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211–225
- Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, Kolch W (Dec 2005). "Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway". The Biochemical Journal. 392 (Pt 2): 249–61
- L.S. Steelman, S.C. Pohnert, J.G. Shelton, R.A. Franklin, F.E. Bertrand, J.A. McCubrey, JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle
- M.J. Garnett, R. Marais, Guilty as charged: B-Raf is a human oncogene, Cancer Cell 6 (2004) 313–319
- Igaz, P., Toth, S. and Falus, A. (2001). Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm. Res. 50, 435-441
- Igaz, P., Toth, S. and Falus, A. (2001). Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm. Res. 50, 435-441.; O’Shea, J. J., Gadina, M. and Schreiber, R. D. (2002). Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 Suppl. S121- S131.
- Aaronson, D. S. and Horvath, C. M. (2002). A road map for those who know JAK-STAT. Science 296, 1653-1655.; Heinrich, P. C., Behrmann, I., Haan, S., Hermanns, H. M., Muller-Newen, G. and Schaper, F. (2003). Principles of interleukin (IL)- 6-type cytokine signalling and its regulation. Biochemical J. 374, 1-20.; Kisseleva, T., Bhattacharya, S., Braunstein, J. and Schindler, C. W. (2002). Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285, 1-24.; O’Shea, J. J., Gadina, M. and Schreiber, R. D. (2002). Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 Suppl. S121- S131
- Lohi, O. and Lehto, V.-P. (2001). STAM/EAST/Hbp adapter proteins – integrators of signalling pathways. FEBS Lett. 508, 287-290. Moustakas, A. (2002). Smadsignalling network. J. Cell Sci. 115, 3355-3356
- R.M. Evans, The nuclear receptor superfamily: a rosetta stone for physiology, Mol. Endocrinol. 19 (2005) 1429–1438.
- T.N. Collingwood, F.D. Urnov, A.P. Wolffe, Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription, J. Mol. Endocrinol. 23 (1999) 255–275.
- K. Scheller, P. Seibel, C.E. Sekeris, Glucocorticoid and thyroid hormone receptors in mitochondria of animal cells, Int. Rev. Cytol. 222 (2003) 1–61; C.E. Sekeris, The mitochondrial genome: a possible primary site of action of steroid hormones, In Vivo 4 (1990) 317–320.
- Protective effect of Cod Liver Oil in Experimentally Induced Gastric Ulceration in Rats
Abstract Views :240 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, PRIST University, Thanjavur-614904, Tamilnadu, IN
2 Columbia Institute of Pharmacy, Near Vidhan Sabha, Tekari, Raipur, Chhattisgarh, Pin-493111, IN
1 Department of Pharmacology, PRIST University, Thanjavur-614904, Tamilnadu, IN
2 Columbia Institute of Pharmacy, Near Vidhan Sabha, Tekari, Raipur, Chhattisgarh, Pin-493111, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 1 (2019), Pagination: 5-10Abstract
Background: Gastric ulcer is a life style disease, observed when gastric mucosa is exposed to the acid-pepsin mixture (APM) for prolonged period of time. The reason to undertake the present study is based on the scientific evidence that the cod liver oil found to possess a significant antioxidant and protective action against inflammation. However, there was no scientific proof established regarding the antiulcer activity of cod liver oil. As inflammation is one the causes of gastric ulcer, the present work was designed to evaluate the anti-ulcer efficiency of cod liver oil in three different ulcerated rat models. Methods: Ulcer was induced through pyloric ligation, ethanol, and aspirin. The effect of Cod liver oil was evaluated by estimating the pH of the gastric juice, volume of gastric juice, ulcer scores, free acidity, total acidity as well as mucin content in the ulcerated rat models. The degree of ulcer protective consequence was explored by comparing the data with standard drugs i.e. omeprazole and sucralfate. Results: Cod liver oil exhibited a significant mucosal protection and anti-secretory action in all three models. Cod liver oil showed percentage ulcer protection of >50% in pyloric ligation, ethanolinduced and aspirin-induced ulcer model when compared to standard drug omeprazole and sucralfate. Conclusion: The findings from the present study indicated that the use of cod liver oil in gastric ulcer may be beneficial as it showed significant mucoprotective and anti-secretory activity in ulcerated rat models.Keywords
Anti-Ulcer, Cod Liver Oil, Pylorus Ligation, Ethanol-Induced Ulcer, Aspirin.References
- Wang Y, Wang S, Lou ZJ, Song XN, Zhang ZY, Li JF, Li S. Anti-ulcer and anti-Helicobacter pylori potentials of the ethyl acetate fraction of Physalis alkekengi L. Var. franchetii (Solanaceae) in rodent. Journal of Ethnopharmacology. 2018; 211: 197-206.
- Amaral GP, De CNR, Barcelos RP, Dobrachinski F, Portella RDL, DaSilva MH, Fachinetto R. Protective action of ethanolic extract of Rosmarinus officinalis L. in gastric ulcer prevention induced by ethanol in rats. Food and Chemical Toxicology. 2013; 55: 48-55.
- Ishihara M, Kojima R, Ito M. Influence of aging on gastric ulcer healing activities of the antioxidants α-tocopherol and probucol. Europian Journal of Pharmacology. 2008; 601: 143-147.
- Mahattanadul S, Ridtitid W, Nima S, Phdoongsombut N, Ratanasuwon P, Kasiwong S. Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. Journal of Ethnopharmacology. 2011; 134: 243-250.
- Ishihara M, Mikio I. Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. European Journal of Pharmacology. 2002; 444; 209-215.
- Miller JP, Faragher EB. Relapse of duodenal ulcer: Does it matter which drug is used in initial treatment? British Medical Journal (Clinical Research Ed). 1986; 293: 1117-1118.
- Basheer AS, Siddiqui A, Paudel YN, Hassan MQ, Imran M, Najmi AK, Akhtar M. Hepatoprotective and antioxidant effects of fish oil on isoniazid-rifampin induced hepatotoxicity in rats. Pharma Nutrition. 2017; 5: 29-33.
- Berenguer B, Trabadela C, Sánchez-Fidalgo S, Quílez A, Mino P, De LPR, Martín-Calero MJ. The aerial parts of Guazuma ulmifolia Lam. protect against NSAID-induced gastric lesions. Journal of Ethnopharmacology. 2007; 114: 153-160.
- Junbo Z, Yongtao Y, Hongbo L, Fenshuang Z, Ruyun L, Chunai Y. Experimental study of sucralfate intervention for paraquat poisoning in rats. Environmental Toxicology and Pharmacology. 2017; 53: 57-63.
- Parmar NS, Ghosh MN. Gastric antiulcer activity of (+) cyanidonol-3 a histidine decarboxylase inhibitor”. European Journal Pharmacology 1981; 69: 25-32.
- Birdane FM, Cemek M, Birdane YO, Gulcin I, Buyukokuroglu ME. Beneficial effects of Foeniculum vulgare on ethanol-induced acute gastric mucosal injury in rats. World Journal of Gastroenterology. 2007; 13: 607-611.
- Robert A, Nezamis J, Lancaster C, Hanchar A. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology. 1979; 77: 433-43.
- Vogel GH, Vogel WH. Drug Discovery and Evaluation. New York, Berlin: Springer-Verlag; 1997. 2nd ed. pp. 488-489.
- Sanford T. Clinical Diagnosis by Laboratory Methods. Davidson and Henry; 1969. 14th ed. pp. 762-784.
- Sabiu S, Ajani EO, Ajao AA, Sunmonu TO, Ibraheem AS, Ibrahim R, Mustapha H, Adekeye AO. Biomembrane stabilization and antiulcerogenic properties of aqueous leaf extract of Gossypium barbadense L. (Malvaceae). Beni-Suef University Journal of Basic and Applied Sciences. 2017; 6: 301-309.
- Hawk PB, Oser BL, Summerson HW. Practical Physiological Chemistry. London: Churchill. 1947. 12th ed. pp. 347.
- Jainu M, Mohan KV, Devi CSS. Protective effect of Cissus quadrangularis on neutrophil mediated tissue injury induced by aspirin in rats. Journal of Ethnopharmacology. 2006; 104: 302-305.
- Lotti VJ, Cerino DJ, Kling PJ, Raymond SL. A new simple mouse model for the in-vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonists. Life Sciences. 1986; 39(18): 1631-1638.
- Ishii Y. Critical studies of pylorus ligated rat (Shay rat). Japanese Journal of Pharmacology. 1969; 19: 125-133.
- Salim AS. Removing oxygen-derived free radicals stimulates healing of ethanol-induced erosive gastritis in the rat. Digestion. 1990; 4(1): 24-28.
- Salim, AS. Gastric mucosal cytoprotection in the rat by scavenging oxygen-derived free radicals. American Journal of Medical Science. 1991; 302: 287-291.
- Hunkar T, Aktan F, Ceylan A, Karasu C. Effects of cod liver oil on tissue antioxidant pathways in normal and streptozotocindiabetic rats. Cell Biochemistry and Function. 2002; 20: 297-302.
- Davenport HW. Is the apparent hypo secretion of acid by patients with gastric ulcer a consequence of a broken barrier to diffusion of hydrogen ions into the gastric mucosa? Gut. 1965; 6(5): 513.
- Davenport HW. Fluid produced by the gastric mucosa during damage by acetic and salicylic acids. Gastroenterology. 1966; 50(5): 487-499.
- Exploring the Protective Effect of Ascorbic Acid on Amoxicillin and Clavulanic Acid-Induced Lipid Peroxidation in Goat Liver Homogenate
Abstract Views :361 |
PDF Views:0
Authors
Affiliations
1 Columbia Institute of Pharmacy, Near Vidhan Sabha, Tekari, Raipur, Chhattisgarh-493111, IN
2 SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Koni, Bilaspur, Chhattisgarh,-495009., IN
1 Columbia Institute of Pharmacy, Near Vidhan Sabha, Tekari, Raipur, Chhattisgarh-493111, IN
2 SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Koni, Bilaspur, Chhattisgarh,-495009., IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 7 (2019), Pagination: 3301-3306Abstract
Background: Therapeutic effect of ascorbic acid on amoxicillin and clavulanic acid-induced lipid peroxidation was carried out in got liver homogenates to investigate the relationship between drug-induced toxicity and drug-induced lipid peroxidation. Methods: The level of malondialdehyde, reduced glutathione and nitric oxide were estimated in control, drug-treated, drug-antioxidant treated and the only antioxidant-treated group at two hours and six hours of incubation time. Results: The level of malondialdehyde in the drug-treated group was found to be increased whereas the level of both reduced glutathione and nitric oxide decreased when compared to control. In the drug-antioxidant treated group, the level of malondialdehyde was found to be reduced whereas the extent of reduced glutathione, nitric oxide increased when compared to the drug-treated group. Conclusion: The present study established the potential of amoxicillin and clavulanic acid to induce lipid peroxidation. On the other hand, ascorbic acid repressed lipid peroxidation to a substantial level. Lipid peroxidation initiation capability of amoxicillin and clavulanic acid might be a contributing factor for their toxicity.Keywords
Malondialdehyde, Nitric Oxide, Reduced Glutathione, Lipid Peroxidation, Amoxicillin, Clavulanic Acid, Ascorbic Acid, Antibiotics.References
- Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. London: Lancet. 2000. pp. 1255-1259.
- Cheeseman KH. Mechanisms and effects of lipid peroxidation. Molecular Aspects of Medicine. 1993; 14(3): 191-197.
- Girotti AW. Mechanisms of lipid peroxidation. Journal of Free Radicals Biology Med. 1985; 1(2): 87-95.
- Gurudharshini N, Madhumitha M, Muthusaravanan S, Perianayaki P, Poornimmashree A, Kumaravel K. A big picture on antimicrobial strategies then and now. Research Journal of Engineering and Technology. 2017; 8(4): 361-364.
- Kasapovic J, Pejic S, Stojiljkovic V, Todorovic A, Radosević-Jelic L, Saicic ZS. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide. Clinical Biochemistry. 2010; 43(16-17): 1287-1293.
- Selvakumar K, Madhan R, Srinivasan G, Baskar V. Antioxidant assays in pharmacological research. Asian Journal of Pharmacy and Technology. 2011; 1(4): 99-103.
- Karunakar Hegde, Cijo Issac, Arun B. Joshi. Inhibitory Response of Carissa carandas ischolar_main extract on lipid peroxidation. Research Journal of Pharmacy and Technology. 2010; 3 (4): 1072-1076.
- Niki E, Yoshida Y, Saito Y, Noguchi N. Lipid peroxidation: Mechanisms, inhibition, and biological effects. Biochemical and Biophysicxal Research Communication. 2005; 338(1): 668-676.
- Jiby E, Rajesh MG, Anish NP, Deepa P, Jayan N. In vitro antioxidant activity of the methanolic extract of Simaruba glauca DC. Asian Journal of Research in Chemistry. 2010; 3(2): 312-315.
- Dima Al Diab, Nour Al Asaad. Comparative analysis of ascorbic acid content and antioxidant activity of some fruit juices in Syria. Research Journal of Pharmacy and Technology. 2018; 11(2): 515-520.
- Shrada BK, Dhanraj M. Role of Vitamin C in body health. Research Journal of Pharmacy and Technology. 2018; 11(4): 1378-1380.
- Todd PA, Benfield P. Amoxicillin/clavulanic acid: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1990; 39(2): 264-307.
- Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects-review of the literature, European Journal of Medical Research. 2001; 6(4): 139-149.
- Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Digestive Diseases and Sciences. 2005; 50(10): 1785-1790.
- Salvo F, Polimeni G, Moretti, Conforti A, Leone R, Leoni O. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: Data from spontaneous reporting in Italy. Journal of Antimicrobial Chemotherapy. 2007; 60(1): 121-126.
- Cundiff J, Joe S. Amoxicillin-clavulanic acid-induced hepatitis. American Journal of Otolaryngol-Head and Neck Medicine and Surgery. 2007; 28(1): 8-30.
- Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Archives of Internal Medicine. 1996; 156(12): 1327-1332.
- Muriel P. Role of free radicals in liver diseases. Hepatology International. 2009; 3(4): 526-536.
- Zhu R, Wang Y, Zhang L, Guo Q. Oxidative stress and liver disease. Hepatology Research. 2012; 42(8): 741-749.
- Beattiea D, Sherlock S. Ascorbic acid deficiency in liver disease. Gut.1976; 17(8): 571-575.
- Karunakar H, Cijo I, Arun B. Joshi. Inhibitory response of Carissa carandas ischolar_main extract on lipid peroxidation. Research Journal of Pharmacy and Technology. 2010; 3 (4): 1072-1076.
- Hamid AA, Aiyelaagbe OO, Usman LA, Ameen OM, Lawal A. Antioxidants: its medicinal and pharmacological applications. African Journal of Pure and Applied Chemistry. 2010; 4(8): 142-151.
- Devbhuti P, Saha A, Sengupta C. Gentamicin induced lipid peroxidation and its control with ascorbic acid, Acta Polania Pharmaceutical Drug Research. 2009; 66(4): 363-369.
- Ray S, Roy K, Sengupta C. Cisplatin-induced lipid peroxidation and its inhibition with ascorbic acid. Indian Journal of Pharmaceutical Sciences. 2006; 68(2): 199-204.
- Devbhuti P, Devbhuti, Saha A, Sengupta C. Effect of ascorbic acid on lipid peroxidation induced by ceftazidime. Journal of Pharmaceutical Sciences and Technology. 2011; 1(1): 51-53.
- Ray S. Evaluation of protective role of ascorbic acid on Flutamide-induced lipid peroxidation. International Journal of Pharm Tech Research. 2012; 4(1): 135-140.
- Aruna P, Shruti B, Archana A, Sameer H, Villasrao J. Tobramycin-induced lipid peroxidation and its control with ascorbic acid. Indo American Journal of Pharmaceutical Research. 2013;3(8): 6076-6082.
- Roy K., De AU, Sengupta C. Evaluation of glutathione and ascorbic acid as suppressors of drug-induced lipid peroxidation, Indian Journal of Experimental Biology. 2000; 38(6): 580-586.
- Gaweł S, Wardas M, Niedworok E, Wardas P. Malondialdehyde (MDA) as a lipid peroxidation marker. Wiadomości Lekarskie. 2004; 57(9-10): 453-455.
- Ayala A, Muoz MF, Argelles S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Medicine and Cell Longevity. 2014; 2014: 1-31.
- Huda MK, Baydaa ST, Sura AS. Effect of the (ɣ-ray) and laser tadiation on the important antioxidant enzyme glutathione (GSH) level in serum. Research Journal of Pharmacy and Technology. 2017; 10(10): 3386-3390.
- Niedernhofer LJ, Daniels JS, Rouzer CA, Greene RE, Marnett LJ. Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. The Journal of Biological Chemsitry. 2003; 278(33): 31426-31433.
- Ferreira ALA, Machado PEA, Matsubara LS. Lipid peroxidation, antioxidant enzymes and glutathione levels in human erythrocytes exposed to colloidal iron hydroxide in vitro. Brazilian Journal of Medicine and Biological Reearch. 1999; 32(6): 689-694.
- Hogg N, Kalyanaraman B. Nitric oxide and lipid peroxidation. Biochimica Et Biophysica Acta. 1999; 1411(2-3): 378-384.
- Hilditch TP. The chemical constituents of natural fats. Champel and Hall Ltd. London. 1956, 3rd ed. pp. 664.
- Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry. 1979; 95(2): 351-358.
- Sun J, Zhang X, Broderick M, Fein H. Measurement of nitric oxide production in biological systems by using griess reaction assay. Sensors. 2003; 3(8): 276-284.
- Supratim Ray. Exploring the protective role of water extract of Spirulina platensis on flutamide-induced lipid peroxidation using 4-Hydroxy nonenal and nitric oxide as model markers. Research Journal of Pharmacy and Technology. 2011; 4(12): 1857-1860.
- Ellman GL. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics. 1959; 82(1): 70-77.
- Ray S. Exploring the protective role of ascorbic acid on Busulfan-induced lipid peroxidation. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2011; 2(4): 702-708.
- Joseph PR, Paul B. Remington: The science and practice of pharmacy. In: Statistics. Lippincott Williams & Wilkins, Philadelphia 2006. 21st ed. pp. 127-150.
- Balakrishnan N, Panda A B, Raj N R, Shrivastava A, Prathani R. The Evaluation of Nitric Oxide Scavenging Activity of Acalypha Indica Linn Root. Asian Journal of Research in Chemistry. 2009; 2(2): 148-150.
- Incidence of Moxifloxacin serious adverse drug reactions in Pneumococcal infections virus infected patients detected by a Pharmacovigilance program by laboratory signals in a Tertiary hospital in Chhattisgarh (India)
Abstract Views :235 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, Columbia Institute of Pharmacy, Near Vidhansabha, Village Tekari, Raipur, (C.G.) 493111, IN
1 Department of Pharmacology, Columbia Institute of Pharmacy, Near Vidhansabha, Village Tekari, Raipur, (C.G.) 493111, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 14, No 4 (2022), Pagination: 237-245Abstract
The direct reporting of adverse drug reactions by patients is becoming an increasingly important topic for discussion in the hospital of Pharmacovigilance. Voluntary adverse drug reaction (ADR) reporting is fundamental to medical drug safety surveillance; however, substantial under-reporting exists and is the main limitation of the system. At this time, hospital accepts consumer reports. The World Health Organization estimates that in 2005 and as well as 2019-2021 pneumococcal infections were responsible for the death of 1.6 million human worldwide. Pneumonia, the lungs become filled with fluid and inflamed, leading to breathing difficulties. For some people, breathing problems can become severe enough to require treatment at the hospital with oxygen or even a ventilator. The pneumonia that COVID-19 causes tends to take hold in both lungs. Moxifloxacin, a fluoroquinolone antibiotic, is used for the treatment of respiratory tract, pelvic inflammatory disease, skin, and intra-abdominal infections. Its safety profile is considered favorable in most reviews but has been challenged with respect to rare but potentially fatal toxicities. The most common adverse drug reaction (ADR) constipation is nausea, vomiting, fatigue, alopecia, drowsiness, myelosuppression, skin reactions, anorexia, mucositis, diarrhoea and Medicines that have been particularly implicated in adverse drug reaction-related hospital admissions include anti-platelets, anticoagulants, cytotoxics, immunosuppressant’s, diuretics, anti-diabetics and antibiotics.Keywords
Moxifloxacin, pneumonia, adverse drug reactions, antibiotic, Fungi, intra-abdominal infections, acute bacterial sinusitis, Fatigue, serious cutaneous reactions, inflammation, adverse event, difficulty breathing.References
- Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. The Lancet. 2011 Apr 9;377(9773):1264-75. 2. Gereige RS, Laufer PM. Pneumonia. Pediatrics in Review. 2013 Oct;34(10):438-56.
- Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. The American journal of medicine. 1994 Apr 1;96(4):313- 20.
- Prayle A, Atkinson M, Smyth A. Pneumonia in the developed world. Paediatric respiratory reviews. 2011 Mar 1;12(1):60-9.
- Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. The Lancet. 1987 Mar 21;329(8534):671-4.
- Kollef MH. Prevention of ventilator-associated pneumonia. Critical Care Infectious Diseases Textbook. 2001:707-17.
- Copetti R, Cattarossi L. Ultrasound diagnosis of pneumonia in children. La radiologia medica. 2008 Mar;113(2):190-8.
- Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Critical care medicine. 2004 Jun 1;32(6):1396-405.
- Morgan MS. Diagnosis and treatment of Panton–Valentine leukocidin (PVL)-associated staphylococcal pneumonia. International journal of antimicrobial agents. 2007 Oct 1;30(4):289-96.
- Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not?. Critical care. 2020 Dec;24(1):1-3.
- Verghese AB, Berk SL. Bacterial pneumonia in the elderly. Medicine. 1983 Sep 1;62(5):271-85.
- Mulholland EK, Simoes EA, Costales MO, McGrath EJ, Manalac EM, Gove S. Standardized diagnosis of pneumonia in developing countries. The Pediatric infectious disease journal. 1992 Feb 1;11(2):77-81.
- Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, Suemura M. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Modern rheumatology. 2009 Feb;19(1):64-8.
- Torres A, El-Ebiary M, Riquelme R, Ruiz M, Celis R. Community-acquired pneumonia in the elderly. InSeminars in respiratory infections 1999 Jun 1 (Vol. 14, No. 2, pp. 173-183).
- Wilkins TR, Wilkins RL. Clinical and radiographic evidence of pneumonia. Radiologic technology. 2005 Nov 1;77(2):106-10.
- Chen X, Yin YH, Zhang MY, Liu JY, Li R, Qu YQ. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology. International journal of medical sciences. 2020;17(16):2511.
- Convertino I, Tuccori M, Ferraro S, Valdiserra G, Cappello E, Focosi D, Blandizzi C. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Critical Care. 2020 Dec;24(1):1-6.
- Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety. Drugs in R&D. 2012 Jun;12(2):71-100.
- Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clinical therapeutics. 2004 Jul 1;26(7):940-50.
- Chen R, Ma W, Yu X, Liu X, Zhu J, Liang H, Wu X, Guo T. Intravenous moxifloxacin in routine hospital treatment of respiratory tract infections in China: results of a multicenter, noninterventional study. International Journal of General Medicine. 2011;4:317.
- Onoh A, Linnebur SA, Fixen DR. Moxifloxacin-induced tinnitus in an older adult. Therapeutic Advances in Drug Safety. 2018 Apr;9(4):219-21.
- Abramova AA, Gavrilova SM. Estimation of ADR'S risk in hospitalized patients with community-acquired pneumonia. In Science Health 2020. Клинические и теоретические аспекты современной медицины 2020 (pp. 37-37).
- Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. Journal of Antimicrobial Chemotherapy. 2003 May 1;51(suppl_1):21-7.
- Hofer-Dueckelmann C. Multiple drugs Various toxicities leading to death in elderly. Reactions. 2011 Dec 10;1381:10.
- Bassis AV. Pneumococcal vaccine First report of cutaneous RosaiDorfman disease. Reactions. 2011 Nov 12;1377:12.
- Ferner RE. Adverse drug reactions. Medicine. 2016 Jul 1;44(7):416-21.
- Härmark L, van Hunsel F, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems. Drug safety. 2015 Apr;38(4):337-47.
- Beijer HJ, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharmacy World and Science. 2002 Apr;24(2):46-54.
- Stipanowich TJ. ADR and the “Vanishing Trial”: the growth and impact of “Alternative Dispute Resolution”. Journal of Empirical Legal Studies. 2004 Nov;1(3):843-912.
- Roberts S, Palmer M. Dispute processes: ADR and the primary forms of decision-making. Cambridge University Press; 2005 Oct 20.
- Webber S, Wilkinson AR, Lindsell D, Hope PL, Dobson SR, Isaacs D. Neonatal pneumonia. Archives of disease in childhood. 1990 Feb 1;65(2):207-11.
- Ding R, Logemann JA. Pneumonia in stroke patients: a retrospective study. Dysphagia. 2000 Mar;15(2):51-7.
- Stevens RM, Teres D, Skillman JJ, Feingold DS. Pneumonia in an intensive care unit: a 30-month experience. Archives of Internal Medicine. 1974 Jul 1;134(1):106-11.
- Cook DJ, Kollef MH. Risk factors for ICU-acquired pneumonia. Jama. 1998 May 27;279(20):1605-6.
- Venkatesan P, Gladman J, Macfarlane JT, Barer D, Berman P, Kinnear W, Finch RG. A hospital study of community acquired pneumonia in the elderly. Thorax. 1990 Apr 1;45(4):254-8.
- Scott JA, Wonodi C, Moïsi JC, Deloria-Knoll M, DeLuca AN, Karron RA, Bhat N, Murdoch DR, Crawley J, Levine OS, O’Brien KL. The definition of pneumonia, the assessment of severity, and clinical standardization in the Pneumonia Etiology Research for Child Health study. Clinical infectious diseases. 2012 Apr 1;54(suppl_2):S109-16.
- Lutfiyya MN, Henley E, Chang LF, Reyburn SW. Diagnosis and treatment of community-acquired pneumonia. American family physician. 2006 Feb 1;73(3):442-50
- Deeper Insights into role of Green Technology for Pollution Free Environment: An updated Review
Abstract Views :106 |
PDF Views:0
Authors
Affiliations
1 Dau Shri Vasudev Chandrakar Kamdhenu Vishwavidyalaya, Anjora, Durg - 491001, (C.G), IN
2 University College of Pharmacy, Pt. Deendayal Upadhyay Memorial Health Sciences and Ayush University of Chhattisgarh, Raipur-492002, Chhattisgarh, IN
3 School of Pharmacy, Chouksey Engineering College, Masturi Road, Bilaspur, Chhattisgarh-495004, IN
1 Dau Shri Vasudev Chandrakar Kamdhenu Vishwavidyalaya, Anjora, Durg - 491001, (C.G), IN
2 University College of Pharmacy, Pt. Deendayal Upadhyay Memorial Health Sciences and Ayush University of Chhattisgarh, Raipur-492002, Chhattisgarh, IN
3 School of Pharmacy, Chouksey Engineering College, Masturi Road, Bilaspur, Chhattisgarh-495004, IN
Source
Research Journal of Science and Technology, Vol 14, No 2 (2022), Pagination: 98-104Abstract
India is the second largest country in the world based on the population that faces many challenges for various environmental issues such as water and air pollution etc. As per the survey by World Bank experts this issues become more exacerbated between 1947 and 1995. Within last decade India has devoted towards putting much efforts to resolve these environmental issues and improving environmental qualities. The major possible issues those contributes to various environmental issues include population growth, deforestation, establishment of industries for growth of economy, burning of fuel, degradation of agricultural lands, drainage of consumer waste into water resources such as rivers, depletion of natural resources such as water, mineral, rocks etc. Another major factor that contributes largely for environmental pollution includes solid waste pollution. As per the data available elsewhere there are more than hundred million tons of solid wastes generated by various cities in India in every year. Now-a-days it has been observed that the tourist places of India are also facing such issues. Green technology is an environment friendly technology which has developed and used to protect the environment and conserves natural resources. This technology is intended to mitigate or reverse the effects of human activity on the environment. Green technology generally uses innovative ideas and methods to create environment friendly products. Green nano-technology that uses green engineering and green chemistry is one of the emerging fields in science and technology. In the matter of environmental pollution and the disposal of waste, Green technology answers to that as well. Among all the possible areas where the creations and growth are possible that include; eco- friendly textiles, biodegradable papers and containers, green energy, green building, organic agriculture, and manufacturing of similar products and materials to support green business. Green technology covers a broad area of production and consumption technologies. The 7R’s of green technology also includes replace, reduce, reliable, repair, reuse, recycle and resources. The green technologies involve the use of environmental technologies for assessment of pollution prevention and control, remediation and restoration. A prevention technology helps to avoid the production of environmentally hazardous substances to minimize damage to the environment.Keywords
Green technology, Green nano-technology, environment, global warming, pollution.References
- Pandey VC and Singh V. Exploring the Potential and Opportunities of Current Tools for Removal of Hazardous Materials From Environments. Market Opportunities in Sustainable Phytoremediation Elsevier, 2019:501-506. doi: 10.1016/B978-0-12-813912-7.00020-X
- Armin R, Shyam D and Martha L. Noble, Environmental Law and Policy in India-Cases, Material and Statutes, 1991.
- Duxbury RMC and Morton, SGC (eds.) Blackstone's Statutes on Environmental law. Third Edition, London: Blackstone Press Limited, 2000
- Kuik OJ. et al. Pollution Control in the South and North: A Comparative Assessment of Environmental Policy Approaches in India and the Netherlands, New Delhi: Sage Publications, 1997.
- Grossman G and A. Krueger 'Economic Growth and the Environment', Quarterly Journal of Economics, 1995 May; Vol. CX ( 2): 353. doi:
- Jain P, Satapathy T, Pandey R. Rhipicephalus microplus: A parasite threatening cattle health and consequences of herbal acaricides for up-liftment of livelihood of cattle rearing communities in Chhattisgarh, Biocatalysis and Agricultural Biotechnology.2020,26; doi: 10.1016/j.bcab.2020.101611
- Mehta A. and Hawkins. 'Integrated Pollution Control and its Impact: Perspectives from Industry', Journal of Environmental Law, 1998; 10(1): 65.
- Satterthwaite D, McGranahan G and Tacoli C. Urbanization and its implications for food and farming.
- Phil. Trans. R. Soc. B, 2010; 365: 2809–2820 doi:10.1098/rstb.2010.0136
- Knudsen Lara (2006). Reproductive Rights in a Global Context Vanderbilt University Press. pp. 2. ISBN 9780826515285.
- Warriner IK and Shah IH, eds., Preventing Unsafe Abortion and its Consequences: Priorities for Research and Action, New York: Guttmacher Institute, 2006. ISBN: 0-939253-76-3.
- Pawson SM, Brin A, Brockerhoff EG, Lamb D et al. Plantation forests, climate change and biodiversity. Biodivers Conserve. 2013; 22: doi: 10.1007/s10531-013-0458.
- S. M. Pawson •A. Brin •E. G. Brockerhoff •D. Lamb •
- T. W. Payn •A. Paquette •J. A. Par
- Cheng MH, Huang H, Dien BS, Singh V. The Costs of Sugar Production from Different Feed stocks and Processing Technologies. https://www.osti.gov/pages/servlets/purl/1495027.
- Renewable Fuels Association (http://www.ethanolrfa.org/).
- Macedo IC. Etanol de Cana de Acucar no Brasil. Presentation at the Seminar on Technologies for Future Ethanol Production in Brazil. Instituto Tecnologia Promon, Sao Paulo, Brazil, 17 April.
- Prakash S, Gupta BN Upmanyu N, Garg G. Rising Importance of Green Chemistry in India: A Study. Research J. Pharm. and Tech, 2010; 3(2):628-628. doi:
- Aithal PS & Aithal S, Ideal Technology Concept & its Realization Opportunity using Nanotechnology. International Journal of Application or Innovation in Engineering & Management. 2015; 4(2):153 - 164.doi:
- Aithal PS and Aithal S, Managing Anticipated Breakthrough Technologies of 21st Century - A Review. International Journal of Research & Development in Technology and Management Sciences.2015; 21(6): 112 – 133.doi:
- Satapathy T, Panda PK. Solid Lipid Nanoparticles: A novel carrier in Drug Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology,2013;5(2):56-61.doi:
- T Satapathy, PK Panda, AK Goyal, G Rath - Evaluation of anti-GERD activity of gastro retentive drug delivery system of itopride hydrochloride .Artificial Cells, Blood Substitutes, and Biotechnology, 2010; 38 (4):200-207.doi: